A Prospective Cohort Study on Warfarin Personalized Medication

Launched by HAOBIN LI · May 20, 2024

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged 65 years and older, taking warfarin, with or without premature vascular aging, regardless of gender.
• • Patients who have not concurrently or intermittently used anticoagulant drugs, including antiplatelet drugs, heparin, low molecular weight heparin, and non-vitamin K-dependent oral anticoagulants, such as dabigatran and apixaban.
• • Signing an informed consent form before blood sample collection.
• Exclusion Criteria:
• • Patients who are allergic to warfarin or lactose.
• • Patients who are receiving immunosuppressive agents or low molecular weight heparin anticoagulants.
• • Patients with bleeding tendencies, blood disorders with platelet counts \> 400 × 10\^9 /L or \< 100 × 10\^9 /L, hemoglobin \> 169 or \< 100 g/L.
• • History of peptic ulcer disease.
• • Malignant tumors, severe multi-organ dysfunction or failure such as heart, liver, and kidney.
• • Neurological disorders such as epilepsy.

Trial Officials